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Key summary points
Aim To review current cardiovascular medications for benefits and potential harms duringCOVID-19.
Findings Several cardiovascular drugs have a potential to protect patients withCOVID-19, although evidence is largely based 
on observational studies and age-specific data arescarce.
Message Most current cardiovascular drugs can be safely continued during COVID-19, butgeneral conditions common in 
older patients must be considered.
Abstract
Purpose In the pathogenesis of severe COVID-19 complications, derangements of renin–angiotensin–aldosterone system 
(RAAS), vascular endothelial dysfunction leading to inflammation and coagulopathy, and arrhythmias play an important 
role. Therefore, it is worth considering the use of currently available drugs to protect COVID-19 patients with cardiovascular 
diseases.
Methods We review the current experience of conventional cardiovascular drugs [angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers, anticoagulants, acetosalicylic acid, antiarrhythmic drugs, statins] as well as some 
The members of EuGMS Special Interest Group in Cardiovascular 
Medicine are listed in acknowledgements.
 * Timo E. Strandberg 
 timo.strandberg@oulu.fi
1 Faculty of Medicine, Laboratory of Clinical Pharmacology 
and Therapeutics, Faculdade de Medicina, Serviço de 
Medicina III, Hospital Pulido Valente, CHULNUniversity 
of LisbonUniversidade de Lisboa, Lisbon, Portugal
2 Department of Internal Medicine, Hospital Curry Cabral, 
Centro Hospitalar Universitário de Lisboa Central, Lisbon, 
Portugal
3 Istanbul Medical School, Department of Internal Medicine, 
Division of Geriatrics, Istanbul University, Capa, 
34093 Istanbul, Turkey
4 Department of Geriatrics and FHU CAR TAG E-PROFILES, 
CHRU de Nancy and INSERM 1116, Université de Lorraine, 
Vandoeuvre-lès-Nancy, France
5 Department of Geriatrics, Centre Hospitalier de Wallonie 
Picarde, Tournai, Belgium
6 Department of Internal Medicine and Gerontology, 
Jagiellonian University Medical College, Cracow, Poland
7 Department of Cardiology, Hospital General Universitario 
Gregorio Marañón, CIBER-CV. Universidad Europea, 
Universidad Complutense, Madrid, Spain
8 Division of Geriatrics, Department of Internal Medicine, 
Erasmus MC University Medical Center, Rotterdam, 
The Netherlands
9 Brighton and Sussex Medical School, University of Sussex, 
Brighton, UK
10 Department of Geriatrics and Intensive Care Unit, University 
of Florence and Azienda Ospedaliero Universitaria Careggi, 
Firenze, Italy
11 Heart Center Trier, Krankenhaus der Barmherzigen Brüder, 
Trier, Germany
12 Helsinki University and Helsinki University Hospital, 
Haartmaninkatu 4, PO Box 340, N00029 Helsinki, Finland
13 University of Oulu, Center for Life Course Health Research, 
Oulu, Finland
726 European Geriatric Medicine (2021) 12:725–739
1 3
other drug classes (antidiabetic drugs, vitamin D and NSAIDs) frequently used by older patients with cardiovascular diseases. 
Data were sought from clinical databases for COVID-19 and appropriate key words. Conclusions and recommendations are 
based on a consensus among all authors.
Results Several cardiovascular drugs have a potential to protect patients with COVID-19, although evidence is largely based 
on retrospective, observational studies. Despite propensity score adjustments used in many analyses observational studies are 
not equivalent to randomised controlled trials (RCTs). Ongoing RCTs include treatment with antithrombotics, pulmonary 
vasodilators, RAAS-related drugs, and colchicine. RCTs in the acute phase of COVID-19 may not, however, recognise the 
benefits of long term anti-atherogenic therapies, such as statins.
Conclusions Most current cardiovascular drugs can be safely continued during COVID-19. Some drug classes may even be 
protective. Age-specific data are scarce, though, and conditions which are common in older patients (frailty, comorbidities, 
polypharmacy) must be individually considered for each drug group.
Keywords Antiarrhytmic · Anticoaculant · Aspirin · Colchicine · COVID-19 · Diabetes · NSAID · RAAS · Statin · Vitamin 
D
Background
Ongoing SARS-CoV-2 (coronavirus) pandemic causing 
COVID-19 is potentially life threatening to older people 
with comorbidities. Males are more vulnerable than females, 
and patients with cardiometabolic diseases have higher risk 
for COVID-19-related severe complications and death. 
Complications are many, but cardiovascular and pulmonary 
ones are important and partly explain the susceptibility of 
patients with cardiovascular disease (CVD) to COVID-19 
complications.
There is increasing knowledge of the potential benefits of 
steroids and specific antiviral treatments (e.g., remdesivir) in 
COVID-19 [1] and vaccination programs have commenced 
globally at end of 2020. However, the outcome of viral infec-
tion does not hinge only on the specific effects of the invad-
ing pathogen, but it also depends on the host response and 
premorbid condition. Immune response of the host may be 
inappropriate, either too strong causing collateral damage 
(cytokine storm), or too weak due to ageing and diseases. 
Differences in immune function (both innate and adaptive) 
between males and females may explain sex differences in 
susceptibility to complications. Besides the immune func-
tion, other factors in the host factors are also important. Any 
infection is potentially more dangerous to a patient with 
CVD as compared to healthy individual, especially because 
of “endotheliitis” [2] predisposing to thrombotic and throm-
boembolic complications.
Hence, it is worthwhile considering using currently 
available cardiovascular drugs to improve prognosis in 
COVID-19 patients with CVD. In the pathogenesis of 
severe COVID-19 complications, vascular endothelial dys-
function seems to play an important role as a root cause 
for coagulopathy, thrombosis, platelet activation and 
heightened inflammatory response [2]. Accordingly, risk 
of myocardial infarction, stroke, deep venous thrombosis 
and pulmonary embolism are increased, and geriatricians 
need to be aware of these complications. Because corona-
virus uses angiotensin-converting enzyme 2 (ACE2) as its 
receptor, molecular mechanisms include derangements of 
renin–angiotensin–aldosterone system (RAAS) [3]. Several 
existing cardiovascular drugs and other drugs have beneficial 
effects on endothelial function/RAAS and on the sequalae 
of their dysfunction. This offers opportunities to improve 
prognosis by re-purposing these therapies.
At the moment evidence is collected from retrospec-
tive, observational studies, which despite propensity score 
adjustments used in many analyses are not equivalent to 
randomized controlled trials (RCTs). A recent analysis of 
trials registered on ClinicalTrials.gov revealed that only 7% 
(n = 114) of interventional clinical trials related to COVID-
19 plan to evaluate cardiovascular therapies, most of them 
in a single center and enrolling < 1000 COVID-19 inpatients 
(88% RCTs). Most common drug classes were antithrom-
botics, pulmonary vasodilators, RAAS-related drugs, and 
colchicine [4].
Although evidence from RCTs is generally considered as 
most powerful, an important caveat related to cardiovascular 
drugs must be mentioned. An RCT performed in the acute 
phase of COVID-19 will not necessarily recognise poten-
tial benefits of chronic use of cardiovascular drugs which 
prevent atherosclerosis and preserve endothelial function 
long term, e.g., statins started before COVID-19 event. Per-
forming an RCT in this setting is extremely difficult, even 
impossible in practice. The situation may be different for 
cardiovascular drugs (e.g., antiarrhythmics, anticoagulants, 
antithrombotics, colchicine) causing acute benefits by their 
effects on inflammation, thrombosis and coagulation.
In the following we shall review available evidence of 
cardiovascular drug treatment, mostly from observational 
studies, and their relationship—benefits or harms—to 
COVID-19. Besides conventional cardiovascular drugs we 
also include a review of nonsteroidal anti-inflammatory 
drugs (NSAIDs, including colchicine), as well as vitamin 
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D, because observational studies have linked low serum 
25-hydroxyvitamin D concentrations with increased CVD 
risk [5]. Geriatric aspects are discussed where feasible, but 
age-specific data are usually lacking.
Data were sought from clinical databases (PubMed, 
Embase, preprints in medXriv) using COVID-19 and spe-
cific key words for each drug class. Interpretations of data 




ACE2 is a receptor present in many tissues throughout the 
human body, with a remarkable expression in the lungs type 
II pneumocytes, and it is important in the control of anti-
atherosclerosis processes and blood pressure [6]. ACE2 is an 
aminopeptidase that converts Angiotensin (Ang) II into Ang 
[1–7]. Ang II exerts powerful vasoconstrictor, pro-fibrotic, 
and pro-inflammatory effects through AT1 receptors. In con-
trast, Ang [1–7] is a potent vasodilator, anti-apoptotic, and 
anti-proliferative agent through Mas receptors. SARS-CoV-2 
uses the ACE2 as a cellular receptor to entry the host cells 
[7]. In particular, the spike protein of SARS-CoV-2 is pro-
cessed by transmembrane protease-serine 2 (TMPRSS2) and 
favors the binding of the spike protein to ACE2 [8].
Angiotensin-converting enzyme inhibitors (ACEi) and 
angiotensin-receptor blockers (ARB) increase the ACE2 
receptor [8]. This led to the hypothesis that these drugs could 
promote the inoculation of SARS-CoV-2 and potentially 
leading to a higher risk of infection and/or disease severity 
[9]. This hypothesis generated social concern among popula-
tion and academics.
Due to the fragility of this harmful assumption many 
medical societies recommended not to withdraw ACEi and/
or ARB due to their proved benefits in many diseases, such as 
hypertension, heart failure, coronary heart disease, diabetes 
mellitus, cerebrovascular disease and chronic kidney disease 
[10–12] and advocate an individualised treatment based on 
age, clinical condition, and co-morbidities of each patient, 
weighing the benefits of an effective treatment against the 
risk of abrupt drug discontinuation [13]. Indeed, subsequent 
systematic reviews and a recent RCT [14] support this rec-
ommendation [15, 16]. Moreover, the infusion of the soluble 
isoform of ACE2 is being studied as a decoy receptor for 
SARS-CoV-2 particles, reducing infectivity and conserving 
cardioprotective actions via Ang [1–8].
Focusing in hypertensive patients, pooled data showed a 
possible benefit on the severity of SARS-CoV-2 infection 
in patients on ACEi and/or ARB treatment [15–18]. Ssen-
tongo et al. [18] reported a significant 35% lower risk of 
COVID-19 mortality (7 studies) among hypertensive hos-
pitalised patients on ACEi/ARB.
Regarding SARS-CoV-2 infection no clear difference 
was found between ACEi and ARB [15]. The putative pro-
tective mechanism is still speculative, but hypothetically 
lung protection may be provided through the activation of 
angiotensin II-receptors type 2 and G protein coupled MAS 
receptors [19].
Thus, current evidence supports that ACEi and ARB are 
not harmful in COVID-19. The evidence to support a poten-
tial benefit in hypertensive subgroup is growing; however, it 
is still based on very low grade of certainty and the results of 
ongoing clinical trials are needed to clarify this hypothesis 
[20–22]. Due the broad and well-known benefits of these 
drugs in cardiovascular risk and blood pressure control, their 
prescription should anyhow be encouraged according to pre-
viously known clinical indications irrespective of age [23].
Other RAAS drugs such as renin inhibitors (aliskiren), 
mineralocorticoid receptor antagonists (spironolactone or 
eplerenone), or even sacubitril, a neprilysin inhibitor, are 
much less studied, but also much less prescribed [24]. Ongo-
ing clinical trials [25] are needed to clarify this theoretical 
hypothesis of benefit regarding mineralocorticoid receptor 
antagonists, till there physicians should follow current rec-
ommendations for prescribing these drugs [26]. Sacubitril/
valsartan association has also been a target for theoretical 
advantages mainly due to potential anti-inflammatory effect; 
however, evidence is still lacking [27, 28].
In conclusion
ACEi and ARB have shown to be safe for COVID-19 
patients and their prescription should be encouraged accord-
ing to previously known clinical indications, also for older 
patients. Data on other RAAS agents and on geriatric popu-
lation are scarce and based on low grade evidence.
Statins
Before COVID-19 era in a randomized placebo-controlled 
trial of unselected acute respiratory distress syndrome 
(ARDS) patients [Hydroxymethylglutaryl-CoA Reductase 
Inhibition with Simvastatin in Acute Lung Injury to Reduce 
Pulmonary Dysfunction-2 (HARP-2) Study], simvastatin 
started acutely was safe but did not affect prognosis [29]. 
This and the potential ACE2 stimulating effect of statins 
initially raised concerns about their effects in SARS-CoV-2 
infection. However, later subgroup analyses of HARP-2 
trial suggested that ARDS patients with hyperinflammatory 
response (one third of all) did benefit from simvastatin treat-
ment [30] raising some hopes for benefits also in COVID-19.
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We now have cumulative evidence from at least 27 obser-
vational studies during COVID-19 pandemic ([31–57], Sup-
plementary Table 1). In all but one study [41, 58] the mor-
tality risk of patients using statins is unchanged or lower 
than that of nonusers of statins after adjustments. The larg-
est analysis about COVID-19-related death is a nationwide 
analysis of people with diabetes in England [type 1 (T1DM), 
n = 264 390; type 2 (T2DM), n = 2,874 020] [31]. Statin 
treatment was associated with a significant 38% lower risk of 
death in type 2 diabetes, and nonsignificant 18% lower risk 
in type 1 diabetes. A meta-analysis of other serious com-
plications (13 studies about death risk) has been recently 
published [59]. Patients in these studies have been usually 
upper middle-aged, average age being around 60 years. An 
analysis of frail Belgian nursing home residents (average 
age 86 years) suggested that statin intake was associated 
with milder clinical symptoms during COVID-19, although 
mortality decrease (49%) was not significant [60].
Several explanations are possible and biological and clini-
cal plausibility of benefits and various pleiotropic mecha-
nisms have been recently reviewed [61, 62]. In addition to 
their established anti-atherosclerotic, antithrombotic and 
anti-inflammatory effects, statins also have immunomod-
ulatory effects which may reduce risk of cytokine storm. 
Furthermore, statins may prevent virus entry by lowering 
cholesterol content of membranes, and even have direct anti-
viral effects. The most probable explanation could be, how-
ever, that patients at risk of cardiovascular complications of 
COVID-19 are better protected when using a statin. Their 
vasculature is apparently more resilient because of athero-
sclerosis prevention. Statins are known to improve endothe-
lial function, and many complications related to COVID-19 
are due to endothelial dysfunction [2]. Outside COVID-19, 
men aged 80 and older using statins had similar prognosis as 
nonusers despite more frequent multimorbidity and higher 
mortality risk [63]. A very recent population-based study in 
Italy showed that statin treatment is beneficial also among 
oldest and frail individuals [64].
Because observational studies of statins have not been 
unequivocal, confirmation from RCTs has been called for 
[59]. However, if a potential benefit of statin treatment is due 
to long term, ongoing use, then trials randomising patients 
during acute COVID-19 will not identify this benefit. To 
prove long-term benefits would require RCTs which cur-
rently seem unrealistic to be executed.
In conclusion
Observational studies have shown that ongoing statin treat-
ment is neutral, or even beneficial, for patients with COVID-
19. Average age of patients in these studies has been around 
60 years, but totality of evidence of statins (vide supra) 
suggests that benefits are independent of age. Ongoing 
statin treatment should not be discontinued, but there is 
no evidence of benefit (nor harm) if statin is started during 
COVID-19. Possible interactions should be considered if 
COVID-19 is being treated with antiretroviral drugs.
Acetylsalicylic acid (ASA, aspirin)
Acetylsalicylic acid (ASA) has well known antithrombotic 
effects, and is routine treatment at low dose in the prevention 
of CVD. ASA has also an anti-inflammatory effect by mod-
ulating the overproduction of pro-inflammatory cytokines 
and chemokines. Eventually, ASA has also antiviral activity 
against DNA and RNA viruses, including human coronavi-
ruses [65, 66]. Therefore, the question arises whether this 
drug might present an efficient treatment in patients with 
COVID-19 and some recent studies have investigated this 
issue.
In a study including 314 COVID-19 patients, ASA was 
independently associated with decreased risk of mechani-
cal ventilation, intensive care unit admission, and in-hos-
pital mortality, whereas there were no differences in major 
bleedings between ASA users and non-users [67]. A large 
observational study which included hospitalised COVID-
19 patients, reported a significantly lower incidence of 
in-hospital death in patients who received intermediate—
compared to prophylactic-dose anticoagulation, and, sepa-
rately, in patients who received in-hospital ASA compared to 
those who received no antiplatelet therapy [68].Conversely, 
a recent meta-analysis has investigated the possible asso-
ciation of ASA use in reducing mortality in patients with 
COVID-19 [69]. This meta-analysis included only 3 studies 
with a total of 1,054 patients, mortality rates were not statis-
tically different between ASA users (22.6%) and non-users 
(18.3%) suggesting no protective effect of ASA in COVID-
19 patients.
In conclusion
Micro- and macrovascular thrombotic events are among the 
hallmarks of COVID-19. The optimal management strategy 
to prevent thrombosis in critically-ill patients, younger and 
older, with COVID-19 remains unknown. A dedicated RCT 
is needed to assess the possible protective role of ASA in 
COVID-19 patients.
Anticoagulants
Hypercoagulopathy leading to thromboembolic events 
is common in older COVID-19 patients and critically ill 
COVID-19 patients have a hypercoagulable profile despite 
the therapeutic (curative, intermediate or full) anticoagulant 
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doses given [70]. Two meta-analysis in hospitalised COVID-
19 found an estimated pooled incidence of venous throm-
boembolism (VTE) of 17% and 21%, with higher rates with 
routine screening [71, 72]. VTE significantly increased the 
odds of mortality by as high as 74% [71]. Also, an elevated 
D-dimer level is a critical risk factor for the mortality of 
the SARS-CoV-2 infection [73]. Thus, several scientific 
societies provided recommendations about stratification of 
VTE risk in hospitalised COVID-19 patients and strongly 
advised prophylactic (low or preventive dose) antithrombotic 
treatment with low molecular weight heparin (LMWH), fon-
daparinux or unfractioned heparin, unless contraindicated. 
[74–76] Some of these recommendations consider the pos-
sibility of giving intermediate-dose LMWH in patients with 
multiple risk factors [72] and extended prophylaxis after dis-
charge [74, 75]. While waiting for trial evidence concerning 
all COVID-19 patients from proper RCTs, a recent paper 
recommends switching all patients already being treated 
with oral anticoagulants (both antivitamin K and direct oral 
anticoagulants) to parenteral heparin at therapeutic levels to 
avoid the risk of over- or under treatment. [77].
Evidence about the effects of anticoagulation in COVID-
19 patients is growing but still limited. A systematic review 
found a benefit of anticoagulants among hospitalised 
COVID-19 adults and suggested that therapeutic doses might 
be associated with better survival compared to prophylactic 
doses [78], while another systematic review showed a slight 
tendency towards a reduction in the mortality rate among 
mechanically ventilated patients with COVID-19 receiving 
therapeutic-dose anticoagulation [79]. However, only few of 
the included studies were of good quality and no information 
was provided regarding various age groups. A meta-analysis 
of hospitalised COVID-19 patients showed that anticoagula-
tion in therapeutic dose was beneficial [80]. An analysis of 
4389 hospitalised COVID-19 adults found that anticoagula-
tion was associated with lower mortality and intubation, with 
a trend towards a higher benefit with therapeutic doses [81]. 
The mean age was only 65 years and was lower in patients 
without anticoagulation. Interestingly, in 26 autopsies, 11 
had thromboembolic disease, not clinically suspected. Data 
in advanced ages are scarce. A small retrospective study in 
older COVID-19 patients with interstitial pneumonia sug-
gested a benefit of direct oral anticoagulants [82].
Alternative potential benefits of heparin have been 
reported in patients with COVID-19, including direct SARS-
CoV-2 antiviral activity and anti-inflammatory properties. 
[83, 84]. However, this is still an area of uncertainty and 
RCTs are ongoing to clarify the best antithrombotic strate-
gies in COVID-19 [85]. The use of anticoagulants should be 
balanced against the risks of bleeding. Intracranial hemor-
rhage seems to be relatively uncommon among COVID-19 
patients but is associated with a high mortality rate and is 
mainly seen in older patients [86].
In conclusion
Anticoagulants, particularly when used in therapeutic 
doses, not just prophylactic dosing, seem to be beneficial 
in hospitalised patients with COVID-19. However, data are 
based on little high-quality evidence and are particularly 
scarce in advanced age population and in patients without 
anticoagulant treatment before admission. Consequently, 
optimal antithrombotic therapy in older patients with 
COVID-19 is yet to be determined.
Beta‑blockers
The use of beta-blockers in older patients with COVID-19 
infection is not controversial, as studies published so far 
have suggested less risk associated with their use [87, 88]. 
At the same time, people with co-morbidities (heart fail-
ure, hypertension, diabetes, ischemic heart disease or atrial 
fibrillation) that are indications for the use of beta-blockers 
are at increased risk for severe complications, including 
death, during infection caused by the SARS-2 virus. These 
two observations indicate that there is no recommendation 
for withdrawal of beta-blockers during COVID-19.
Moreover, there are suggestions about the beneficial 
effects of beta-blocking agents, which would result from 
the potential role of beta-blockade in inhibiting the inflam-
matory response [89]. Several studies have indicated the 
role of catecholamines and stimulation of beta receptors in 
promoting the inflammatory response, as the overall effect 
of β2-adrenergic stimulation is an exacerbation of inflam-
mation, promotion of B cell antibody production, and 
stimulation of dentritic cells and macrophages to secrete 
proinflammatory cytokines [89]. The multi-organ failure 
observed during cytokine storm can be partially linked to 
the activation of beta-receptors in many SARS-CoV-2 tar-
get organs such as lungs, heart, gastrointestinal tract, liver, 
vascular smooth muscle, and skeletal muscle. Moreover, 
β2-adrenergic receptors are expressed by the cells of the 
immune system, including macrophages, dentritic cells, 
and T and B lymphocytes.
The following hypothesised mechanisms of potentially 
beneficial effects of beta-blockade in different phases of 
COVID-19 have been proposed [90]:
• reduction of the SARS-CoV-2 host cell entry.
• decrease in proinflammatory cytokines production and 
inhibit cytokine storm.
• potential benefit in septic shock and ARDS.
• reduction of the hypercoagulation state.
• improvement of oxygenation level by beta-blockers.
• potential reduction of mucus hypersecretion.
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In conclusion
Taking into account the results of observational studies beta-
blockers should not be stopped during COVID-19, and this 
applies also to older patients. Whether or not the anti-inflam-
matory effect of beta-blockers plays any clinically important 
role in prevention or treatment of cytokine storm has to be 
confirmed in prospective research and RCTs.
Antiarrhythmic drugs (other 
than beta‑blockers)
Arrhythmias are related to an increased morbidity and mor-
tality in COVID-19, and their inpatient incidence is between 
7.9% and 16.7%, possibly increasing up to 44% in patients 
admitted to intensive care unit [91]. Antiarrhythmic drugs 
diversely affect ion channels [92], of which particularly 
those mediating the selective passage of  Ca2+ across cell 
membranes, modulate virus life cycles and play an important 
role in virus–host interaction [93–95]. Hence, bearing in 
mind the mechanisms of action and considering pleiotropic 
effects of some antiarrhythmic drugs, as well as the viral life 
cycle, it is natural to postulate they could work as antiviral 
drugs and affect SARS-CoV-2 infection.
In a large population study to assess the protective effect 
of several drugs acquired at the pharmacies < 30 days pre-
ceding diagnosis of severe COVID-19, flecainide was one 
of the drugs associated with significantly reduced risk of 
infection and hospitalisation [96]. On a bioinformatic level, 
propafenone revealed activity against the main protease of 
SARS-CoV-2 and influenced its virulence. Regardless these 
promising results, clinical studies are obligatory [97].
Amiodarone, used to control a wide range of atrial and 
ventricular arrhythmias, has been suggested as potential 
drug for prevention or treatment of COVID-19 [92, 98]. The 
ReCOVery-SIRIO, a multicenter study, aims to determine 
the role of amiodarone or verapamil, in hospitalised patients 
within the initial stage of COVID-19 [93, 95]. Dronedarone, 
a noniodinated and less lipophilic derivate developed to treat 
atrial fibrillation and flutter, has a better safety profile than 
amiodarone [92, 99].
Ca2+-channel blockers diltiazem and verapamil, applied 
in the prevention and treatment of supraventricular tachy-
cardias [92], have been hypothesised to affect SARS-CoV-2 
infection by inhibiting  Ca2+ entry via L-type voltage-gated 
 Ca2+ channels, with ensuing antiviral effects [93, 95].
Also digoxin, a cardiac glycoside used in the rate con-
trol of atrial fibrillation and flutter [92] has antiviral activity 
[100]. There is scarce research relating the remaining antiar-
rhythmic drugs, including ivabradine, a selective I(f) current 
inhibitor to COVID-19.
In conclusion
Use of antiarrhythmic drugs in COVID-19 should be similar 
to patients in other diseases [98, 101]. Dose adjustments 
may be needed in older patients, and with renal or hepatic 
impairment [92, 102]. Despite intriguing experimental data 
and hypotheses of antiviral effects, these drugs are not indi-
cated as a prophylactic therapy of SARS-CoV-2 infection 
at the moment.
Antidiabetic drugs
Diabetes is one of the most important comorbidities related 
to the severity of SARS-CoV-2 infection [103] and often 
associated with CVD. Reported prevalence of diabetes 
among COVID-19 patients ranges from 5% to as high as 
58%, depending on the patient and study criteria [104, 105].
Recommendations for diabetes treatment in COVID-19 
advocate intensification of glycaemic control as a means of 
primary prevention for a severe illness and antidiabetic drugs 
should not be discontinued in the absence of specific con-
traindications [106]. Moreover, some antidiabetic drugs have 
shown pleiotropic activity added to the glycaemic control 
and may represent benefits to fight SARS-CoV-2 infection 
[103].Moreover, some antidiabetic drugs have shown pleio-
tropic activity added to the glycaemic control, particularly 
potential antiproliferative and immunomodulatory effects, 
and may represent benefits to fight SARS-CoV-2 infection 
[103].
Metformin
Metformin was related to a decreased risk of mortality 
in patients with chronic lower respiratory diseases [104]. 
Regarding COVID-19, observational studies have suggested 
that metformin use in hospitalised patients with T2DM is 
associated with reduced mortality [107]. In the CORO-
NADO (Coronavirus SARS-CoV-2 and Diabetes Outcomes) 
multicenter study (n = 1317), metformin use on admission 
(56.6%) was associated with a 41% reduced 7-day mortality 
risk [108]. A large US study showed that the reduction in 
mortality is gender-dependent: 24% for females and non-
significant for males in propensity-matched model [109]. 
The associated benefits of metformin on mortality due to 
COVID-19 are not restricted to patients with severe disease 
or hospitalisation. A retrospective analysis in nursing homes 
demonstrated similar results, showing that residents taking 
metformin had a significantly reduced 30-day mortality from 
COVID-19 diagnosis compared to residents without antidia-
betic drugs [110].
Regarding safety, metformin may induce lactic aci-
dosis in cases of multi-organ dysfunction necessitating 
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discontinuation of the drug [111, 112]. However, it can be 
safely continued in stable patients with normal oral intake 
and do not have nausea and vomiting. Dosing adjustment or 
interruption should be performed according to renal function 
[103, 113–115].
Thiazolidinediones
Experimental studies suggest that pioglitazone may upreg-
ulate ACE2 in insulin-sensitive tissues and, although this 
effect in the lung is still uncertain, this supposed increase 
in ACE2 expression has raised some concerns about the use 
of this drug in patients with diabetes and COVID-19 [104, 
115–117]. Moreover, thiazolidinediones seem to increase the 
risk of pneumonia when compared to sulfonylureas and, tak-
ing into consideration the risk of fluid retention, it could be 
judicious to withhold PPAR-γ agonists in acutely ill patients 
[104, 115, 116].
Dipeptidyl peptidase‑4 inhibitors (DPP‑4i)
There is no sustained evidence to determine the impact of 
DPP-4i on clinical outcomes related to COVID-19 [103, 
104, 107, 108, 114, 118–120]. As DPP-4i exhibit an opti-
mal safety profile, even in fragile people, they remain a 
valid therapeutic option for the management of patients with 
T2DM and COVID-19 who are stable and with satisfac-
tory oral intake [115, 120]. However, dose adjustments may 
be required according to renal function and more data are 
needed for recommendations in critically ill patients [114, 
115].
Glucagon‑like peptide‑1 receptor agonists (GLP‑1 
RAs)
GLP-1 RAs have shown to be particularly effective in obese 
T2DM patients and are indicated for patients at high risk 
or established atherosclerotic CVD due to evidence of car-
diovascular protective effects [113, 121]. However, none of 
the studies have demonstrated clear influence on outcomes 
related to COVID-19, and there is lack of evidence regard-
ing the safety of use of GLP-1 RA in critically ill patients. 
Their use should be carefully considered or discontinued in 
the most fragile patients [114, 115, 121].
Sodium‑glucose co‑transporter‑2 inhibitors 
(SGLT2is)
SGLT2is are highly effective in the treatment of diabetes and 
have been strongly associated with improved CVD outcomes 
[103, 113, 114]. A multicenter RCT ((Dapagliflozin in Res-
piratory Failure in Patients with COVID-19—DARE-19) is 
underway to investigate the role of dapagliflozin in reducing 
disease progression, complications and all-cause mortality 
in COVID-19 [122].
SGLT2is are associated with an increased risk of vol-
ume depletion and euglycemic ketoacidosis, which could 
be greater in the context of severe infections. Therefore, it 
is recommended to withhold them in hospitalised patients 
with COVID-19, and also in very unwell outpatients [106, 
109, 113, 114, 116, 120, 122].
Sulfonylureas
The number of patients using sulfonylureas has been low in 
observational studies of COVID-19, probably due to adverse 
effects [107, 122]. Although sulfonylureas and glinides 
apparently do not directly affect SARS-CoV-2, it is recom-
mended to withhold them in patients with compromised oral 
intake or severe illness, to avoid the risk of hypoglycemia 
[114–116, 123].
Insulin
Insulin is a safe choice under most circumstances, being 
the only therapy for people with T1DM and considered the 
first-line treatment in hyperglycaemic critically ill patients 
[113, 117].
Several studies have shown that insulin therapy was 
linked to poor prognosis in COVID-19 [107, 108, 110]. 
However, it is important to underline that the poorer out-
comes are probably due to the fact that use of insulin reflects 
more advanced diabetes and patients who are often older 
and frailer. Indeed, insulin often remains the only drug to 
achieve glucose control in critically ill patients, particularly 
those in intensive care units, where other glucose lowering 
drugs must be discontinued [105]. Moreover, given the wide 
clinical spectrum of COVID-19 and potential to deteriorate 
rapidly, it is reasonable to consider early introduction of 
insulin on hospital admission [116]. Hypoglycaemia should 
be avoided as it is also related to unfavourable outcomes 
[114, 115].
In conclusion
Data linking diabetes and COVID-19 are growing but still 
limited, especially in older population. An optimal glycae-
mic control is crucial to improve prognosis in COVID-19 
patients with diabetes and pharmacological treatment must 
be carefully managed to avoid serious adverse reactions, 
particularly in the most fragile patients. There is evidence 
of extrapancreatic pleiotropic effects for some antidiabetic 
drugs that can represent a potential benefit in the context of 
COVID-19, but these effects specifically in older patients 
are unknown.
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Vitamin D
Epidemiologic data suggest that the risk of infectious 
diseases is higher when 25-hydroxyvitamin D [25(OH)
D] levels are < 20 ng/mL (50 nmol/L) and risk decreases 
with higher concentrations [124]. In RCTs vitamin D sup-
plementation of 10–25 µg (400–1000units) a day had a 
small protective effect against acute respiratory infections 
[125, 126]. COVID-19 severity and mortality rates are 
higher in older adults, African Americans, patients with 
diabetes, chronic lung disease, and CVD—all groups with 
low vitamin D levels. Ecological studies suggest that high 
latitudes and winter season—risk factors for low vitamin 
D—are associated with higher mortality rates in COVID-
19 [125, 126]. Consequently, the fact that risk for vita-
min D deficiency overlaps with factors associated with 
mortality from COVID-19 has stimulated studies on the 
role of vitamin D in COVID-19, especially from a therapy 
viewpoint.
Because epidemiologic associations may be explained 
by the “healthy user” effect [127] clinical studies are 
needed. These have revealed mixed findings between 
serum 25(OH)D levels and risk for COVID-19 [128], and 
clear support for causality remains undetermined [126].
The subsequent question is whether vitamin D replace-
ment or treatment with higher pharmacological doses may 
have a beneficial effect on COVID-19 risk, and/or severity 
and mortality. There is a strong rationale to study these 
effects [127]. The ability of adequate vitamin D status to 
prevent mortality associated with COVID-19 has been 
suggested by an increasing number of observational stud-
ies [129–131]. An example is the recent, large analysis 
from UK Biobank (n = 8297), where habitual use of vita-
min D supplements was significantly associated with an 
adjusted 34% lower risk of COVID-19 [132]. Yet, there 
are also conflicting findings [124, 127, 130]. Regarding 
effect in treatment of COVID-19, a one small (n = 76), 
low quality RCT reported significantly reduced disease 
severity among patients given a high dose of vitamin D 
on admission [133]. Another small trial (n = 40) reported 
that patients with mild or asymptomatic COVID-19 and 
given high-dose vitamin D supplementation [1500  µg 
(60,000 units) daily for 7 days] more likely were negative 
at third week [134]. On the other hand, a single oral dose 
of 5000 µg (200,000 units) of vitamin D3 did not influ-
ence length of stay among patients with severe COVID-19 
[135].
Currently, several larger, placebo-controlled trials with 
vitamin D are in progress [124, 127, 136, 137].
It is suggested that the effect of vitamin D is promi-
nent when there is either extreme deficiency, or high 
therapeutic doses are used. Generally, vitamin D is safe, 
especially if the dose does not exceed the upper tolerable 
limit [129]. Suggested dosing of daily vitamin D varies: 
15–25 µg (600–1000 units, 124), 25–50 µg (1000–2000 
units, 129), or at daily equivalent doses of 25–100 µg 
(1000–4000 units), daily or weekly [127]. In general, daily 
dosing is recommended—rather than higher doses weekly 
or monthly [124, 129]—and mega-doses are not recom-
mended. As target level in serum, some authors suggest 
a level > 20 ng/mL (50 nmol/L) [129], many others set 
the target at 30 ng/mL (75 nmol/L)[127]. Nevertheless, 
one should consider that the beneficial effect is expected 
to be small and may take some time (months) to develop 
[129]. These conclusions may change by the newly emerg-
ing data.
Of note, the UK National Institute for Health and Care 
Excellence (NICE) COVID-19 rapid guideline: vitamin D 
(https:// www. nice. org. uk/ guida nce/ ng187) has been pub-
lished very recently, indicating the validity of their existing 
advice that adults in the UK should take 10 µg (400 units) of 
vitamin D daily between October and March, while certain 
populations at risk of vitamin D deficiency should consider 
taking vitamin D daily throughout the year.
In conclusion
The clinicians should consider the possibility of lowering 
the impact of COVID-19 by ensuring adequate vitamin D 
replacement in populations, where vitamin D deficiency 
is prevalent. These often include older adults with CVD. 
Although the evidence of benefit in COVID-19 is largely 
observational, adequate vitamin D intake is nevertheless rec-
ommended for older persons to preserve bone health [138].
Non‑steroidal anti‑inflammatory drugs 
(NSAIDs) including colchicine
NSAIDs are widely used also by patients with CVD for 
pain, antipyretic effect, and management of inflammatory 
diseases. However, there have been concerns about the safety 
of NSAIDs use during COVID-19. It was speculated that 
ibuprofen can be detrimental when taken to treat general 
symptoms of a SARS-CoV-2 infection [139] However, on 
March 2020, the WHO released a statement after a litera-
ture review, that there is no evidence against the use of ibu-
profen in COVID-19 patients [140] which was followed by 
confirmatory statements of FDA, EMEA, and others. These 
statements supported the continued use of NSAIDs for anal-
gesia/antipyretic treatment and recommended continuation 
of regular therapy. The use of NSAIDs, such as ibuprofen, 
was not associated with severe COVID-19 or increased mor-
tality in a Danish cohort study of 9236 patients [141]. Of 
them 248 (2.7%) had presumably taken an NSAID in the 
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30 days before being positive diagnosed for SARS-CoV-2. 
There were no significant differences between NSAID users 
and non-users for 30-day mortality (6.3% of vs. 6.1%), hos-
pitalisation (24.5% vs. 21.2%), or intensive care unit admis-
sion (4.9% vs. 4.7%) [141]. An additional systematic review 
of NSAIDs in various respiratory infections including two 
RCTs gave inconclusive results mainly due to low quality 
of studies [142].
On the other hand, anti-viral and anti-inflammatory 
effects of NSAIDs could also be theoretically beneficial in 
COVID-19. Several in vitro and in vivo studies have evalu-
ated NSAIDs in viral infections. The proposed mechanism 
of action, e.g., by indomethacin, is inhibition of intracellu-
lar viral RNA replication [143] and interference with virus-
mediated signal transduction pathways and transcription 
factors. As a clinical example, indomethacin (25–50 mg 
of twice daily) treatment in > 60 non-hospitalised patients 
with suspected and confirmed COVID-19 was associated 
with symptomatic relief of incessant coughing and COVID-
19-associated general symptoms [144]. Besides anti-viral 
properties, NSAIDs may have anti-inflammatory properties, 
e.g., by attenuating cytokine storm in ARDS. However, data 
are limited and clinical evidence is lacking so far.
A highly intriguing new observation is the potential role 
of colchicine, an old anti-inflammatory drug used for gout 
and pericarditis, in COVID-19. Recent RCTs in patients with 
coronary artery disease have shown significant reduction 
of CVD events with colchicine treatment [145]. A meta-
analysis of eight studies included 5778 COVID‐19 patients 
and 2668 patients who received colchicine treatment [146]. 
Of the eight studies, three were RCTs, two and two retro-
spective and prospective cohort studies, respectively, and the 
remaining one was a case‐control study. In the pooled analy-
sis colchicine was associated with improvement in outcomes 
of COVID‐19 by 57%, and a reduction of mortality also 
by 57%. The reduction of outcomes was somewhat smaller 
(49%) in RCTs than in observational studies (59%), but 
still significant [146]. In January 2021, the Montreal Heart 
Institute announced that in the large, international COLCO-
RONA clinical trial with non-hospitalised patients, colchi-
cine, as compared to placebo, has reduced hospitalisations 
significantly by 25%, the need for mechanical ventilation 
or deaths nonsignificantly by 50% and 44%, respectively, 
among 4159 patients in whom the diagnosis of COVID-19 
was proven by a naso-pharyngeal PCR test [147]. At the 
moment the data for COLCORONA are only available as 
a preprint.
In conclusion
Although there is no safety signal for detrimental effects 
of NSAID use in COVID-19, NSAID use need to be care-
fully evaluated in patients with CVD due to its association 
with kidney injury, and gastrointestinal complications, and 
increased risk of bleeding. This is especially important in 
older patients with COVID-19. Benefits and risks need to 
be individually evaluated. Currently, there is no evidence for 
initiation of NSAIDs as a specific therapeutic approach in 
COVID-19 patients. However, results from the meta-analysis 
and COLCORONA trial are apt to change this conclusion 
for colchicine.
Overall conclusion
Summary of the benefits and potential harms of various drug 
classes and recommendations for their use in COVID-19 
is presented in Table 1. While these recommendations are 
independent of patients’ age, drug-specific cautions due to 
frailty, renal or hepatic insufficiency, and potential comor-
bidities, contraindications, and drug interactions should be 
individually considered for all drug groups.
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